1[10]
|
Male |
41 |
140 |
140 |
Dyspnea, cough,
edema |
NA |
+ |
- |
26 |
Discontinuation + glucocorticoids + diuretics,
replacement of oral nilotinib treatment |
2.5 |
Improved |
2[11]
|
Male |
48 |
140→50 |
140→50 |
Dyspnea,
jugular vein dilation, edema, hepatosplenomegaly |
61 |
+ |
+ |
21 |
Discontinuation + diuretic + glucocorticoids, dasatinib reduction
therapy, discontinuation after exacerbation |
12 |
Improved |
3[12]
|
Male |
70 |
140 |
140 |
Dyspnea |
NA |
+ |
- |
32 |
Discontinued + Sildenafil |
7 |
Improved |
4[13]
|
Female |
53 |
100→70 |
100→70 |
Dyspnea,
edema, hepatosplenomegaly |
65-70 |
- |
- |
31 |
Discontinuation +
sildenafil + diuretic, replacement of oral nilotinib treatment |
2 |
Improved |
5[14]
|
Male |
47 |
140→100 |
140→100 |
Dyspnea,
jugular vein dilation, edema, hepatosplenomegaly |
61 |
+ |
+ |
39 |
Discontinuation + sildenafil and replace oral nilotinib treatment |
6 |
Improved |
6[15]
|
Female |
61 |
140→70 |
140→70 |
Dyspnea |
NA |
+ |
+ |
27 |
Discontinuation + sildenafil and replace oral
nilotinib treatment |
4 |
Improved |
7[16]
|
Male |
57 |
70 |
70 |
Dyspnea, edema |
elevated |
- |
- |
37 |
Sildenafil + diuretic, discontinuation and
replacement with nilotinib treatment |
3 |
Improved |
8[17]
|
Female |
23 |
140 |
140 |
Dyspnea |
114 |
+ |
+ |
35 |
Discontinuation + prostaglandin + diuretic, replacement of
oral nilotinib treatment |
9 |
Improved |
9[18]
|
Male |
33 |
100 |
100 |
Dyspnea |
105 |
- |
- |
63 |
Discontinuation + sildenafil and replace oral nilotinib
treatment |
3 |
Improved |
10[19]
|
Male |
50 |
100 |
100 |
Dyspnea, cough,
chest pain |
60 |
+ |
- |
48 |
Discontinuation + sildenafil and replace
oral nilotinib treatment |
22 |
Improved |
11[20]
|
Male |
43 |
140 |
140 |
Dyspnea |
90 |
+ |
+ |
69 |
Discontinuation + sildenafil + calcium channel blocker +
diuretic, switch to oral treatment with Ponatinib |
1 |
Improved |
12[20]
|
Male |
52 |
140 |
140 |
Dyspnea |
75 |
+ |
+ |
38 |
Discontinuation + sildenafil and replace oral nilotinib
treatment |
3 |
Improved |
13[21]
|
Male |
55 |
100 |
100 |
Chest tightness,
fatigue, edema |
115 |
+ |
+ |
36 |
Discontinuation + diuresis with
intermittent oral dasatinib treatment |
36 |
Improved |
14[9]
|
Female |
61 |
140 |
140 |
Dyspnea, cough |
NA |
+ |
- |
26 |
Discontinuation + tadalafil + ambrisentan + diuretic,
replacement of oral treatment with nilotinib |
4 |
Improved |
15[22]
|
Male |
52 |
NA |
NA |
Dyspnea |
NA |
- |
- |
48 |
Discontinuation + Ambrisentan, replacement of oral bosutinib
treatment |
NA |
Na |
16[8]
|
Female |
46 |
70 |
70 |
Dyspnea |
98 |
+ |
+ |
144 |
Discontinuation + Tadalafil + Ambrisentan |
2 |
Improved |
17[23]
|
Male |
67 |
100 |
100 |
Dyspnea, edema |
NA |
+ |
- |
42 |
Discontinuation + sildenafil and replace oral imatinib
treatment |
1 |
Improved |
18[24]
|
Male |
24 |
100 |
100 |
Dyspnea, edema |
NA |
+ |
- |
48 |
Discontinuation + sildenafil + bosentan + diuretic,
replacement of bosutinib treatment |
6 |
Improved |
19[25]
|
Female |
46 |
140 |
140 |
Dyspnea, chest
tightness |
78 |
+ |
+ |
59 |
Discontinuation + tadalafil + bosentan,
replacement of oral imatinib treatment |
3 |
Improved |
20[26]
|
Male |
63 |
140→50 |
140→50 |
Dyspnea,
jugular vein dilation, hepatosplenomegaly |
NA |
- |
- |
60 |
Discontinuation + tadalafil + macitentan + sellepag and replacement of
oral imatinib treatment |
12 |
Improved |
21[27]
|
Female |
73 |
NA |
NA |
Dyspnea |
NA |
+ |
- |
9 |
Discontinuation, replacement of oral imatinib treatment |
12 |
Improved |
22[28]
|
Female |
59 |
140 |
140 |
Dyspnea, chest
pain |
100 |
- |
+ |
54 |
Discontinuation + tadalafil + macitentan +
diuretic + bronchodilator, replacement of nilotinib treatment |
11 |
Improved |
23[29]
|
Male |
38 |
NA |
NA |
Dyspnea, chest
pain, cough, syncope |
57 |
+ |
- |
18 |
Discontinuation + Anrisentan +
Diuretic |
6 |
Improved |
24[5]
|
Male |
56 |
100 |
100 |
Chest tightness,
shortness of breath |
117 |
+ |
+ |
47 |
Discontinuation + liothyronine
+ diuretic, resumed dasatinib treatment, replaced nilotinib + bosentan +
sildenafil after exacerbation |
14 |
Improved |
25[30]
|
Male |
24 |
140 |
140 |
Dyspnea, jugular
vein dilation |
67 |
+ |
- |
10d |
Discontinue the drug |
1W |
Improved |
26[31]
|
Male |
50 |
140 |
140 |
Dyspnea, jugular
vein dilation, edema, hepatosplenomegaly |
70 |
+ |
- |
24 |
Discontinuation + bosentan + glucocorticoids + diuretics, replacement of
nilotinib treatment |
9 |
Improved |
27[32]
|
Female |
47 |
100 |
100 |
Dyspnea, chest
tightness |
80 |
+ |
+ |
15 |
Discontinuation + sildenafil +
glucocorticoids + diuretics + tigecycline |
4 |
Improved |
28 |
Male |
13 |
60 |
60 |
Cough, fatigue,shortness of breath |
137 |
+ |
+ |
75 |
Discontinuation + diuretic + digitalis + bosentan + poliovir
+ sildenafil + captopril, replacement of nilotinib treatment |
3 |
Improved |
29 |
Female |
5 |
40→50 |
40→50 |
With no clinical manifestation |
65 |
- |
- |
6 |
Discontinuation + captopril + ryanodine, replacement of
imatinib treatment |
1 |
Improved |